Where Cannabis Is Legal Around the World

Cannabis policy has changed faster over the past fifteen years than in the century before it. The global picture is no longer prohibition with a few exceptions — it is four distinct models operating simultaneously, often in neighbouring countries.

The Four Models

Full legalization. Adult-use cannabis is legal, regulated and taxed, with a licensed commercial supply chain. Uruguay was first, in 2013. Canada followed nationally in 2018. In the United States, a majority of states have legalized adult use while federal prohibition remains in place — a contradiction with real consequences for banking, transport and enforcement.

Medical-only frameworks. Cannabis is available by prescription or recommendation through a regulated system, with recreational use still prohibited. This is now the most common model. Germany, Australia, Israel, the United Kingdom, and a substantial number of other countries operate versions of it, though access varies from genuinely accessible to nominal.

Decriminalisation. Possession of small amounts is not a criminal offense, but supply remains illegal. Portugal is the widely cited example, having decriminalised all drug possession in 2001 and redirected resources toward treatment. Decriminalisation addresses criminal justice consequences without creating a legal supply, which is a meaningful difference.

Prohibition. Still the position in much of Asia, the Middle East and Africa, in some cases with severe penalties.

How Medical Access Differs in Practice

“Medical cannabis is legal” describes very different realities depending on where you are.

Some programs are broadly accessible — Missouri, for example, publishes a list of qualifying conditions but ends it with a catch-all that leaves the decision to the certifying provider’s professional judgment. Others restrict eligibility to a narrow set of conditions, usually after conventional treatments have failed, with specialist approval required. A few permit cannabis-derived medicines only for a handful of licensed indications, which is closer to pharmaceutical regulation than to a cannabis program.

The practical test is not whether a framework exists but how many patients actually receive product through it. On that measure, several countries with medical frameworks have very low real-world access.

What Legalization Does to Testing Standards

This is where the models diverge most sharply, and it is the part with direct consequences for product quality.

Countries that regulate cannabis as a medicine generally apply existing pharmaceutical standards — Good Manufacturing Practice, pharmacopoeial monographs specifying methods and limits, and full batch documentation. This produces a rigorous, standardized regime, with correspondingly high production costs and slow routes to market. Several European medical programs work this way.

Countries that regulate cannabis as its own category write bespoke rules. Canada does this federally, which gives it one consistent national standard. The United States does it state by state, which produces the patchwork described in how testing rules differ across states.

Decriminalised markets have no testing regime at all, because there is no legal supply chain to regulate. Consumers get the criminal-justice benefit without the product-safety benefit — which is a genuine limitation of the model, and the reason contamination risks in untested cannabis products persist there.

The International Treaty Layer

Cannabis is controlled under three United Nations conventions, principally the 1961 Single Convention on Narcotic Drugs. Countries legalizing adult use are therefore in tension with treaty obligations, which is part of why several have taken slower or more constrained routes than domestic politics alone would explain.

The 2020 reclassification of cannabis under the 1961 Convention — removing it from the schedule reserved for substances with no recognized medical value — was a meaningful signal, though it did not change any country’s obligations regarding non-medical use.

What Legalization Consistently Produces

Across markets that have legalized, several patterns recur reliably enough to be predictable.

An initial supply shortage, then oversupply. Almost every legalized market has followed this arc. Licensed production takes time to come online, then overshoots.

Price decline. Legal prices start above illicit prices, then fall — sometimes below them — as production scales.

Consolidation. Early markets fragment across many small operators; capital requirements and compliance overheads then favor scale.

Tightening regulation. Initial frameworks are usually revised toward stricter testing, labeling and marketing rules once problems surface. Requirements very rarely loosen.

Persistent illicit supply. Legal markets do not eliminate illicit ones, particularly where taxes are high or licensed retail is thin. Which means untested product remains in circulation even in mature legal markets.

Why This Matters Beyond Policy Interest

For operators, the international picture is the clearest available preview of where domestic regulation is heading. Markets that legalized earlier have already worked through the problems newer markets are encountering, and their responses — mandatory accreditation, standardized methods, blind proficiency testing, tighter marketing rules — are the likely template.

Pharmaceutical-grade frameworks in particular show what cannabis testing looks like when it is held to the standard applied to medicines. Some of that is already arriving in US state programs. More on the trajectory in the future of cannabis lab testing and the future of the cannabis industry.

For how the regulatory framework in the United States reached its current shape, see from the Marihuana Tax Act to Amendment 3.